Federal Court rejects patent owner’s res judicata claim against generic manufacturer’s defence
The Federal Court has dismissed a summary judgment motion brought by a pharmaceutical company which had alleged that a patent invalidity defence claimed by a generic drug manufacturer was res judicata...To view the full article, register now.
Already a subscriber? Click here to view full article